BBOX1-Related Carnitine Biosynthesis Deficiency

Mendelian Pathograph 21 Show in embeddings browser Fatty Acid Oxidation Disorder Inborn Error of Metabolism

BBOX1-related L-carnitine biosynthesis deficiency is a very recently delineated autosomal recessive inborn error of the endogenous carnitine synthesis pathway. BBOX1 encodes gamma-butyrobetaine hydroxylase, the cytosolic dioxygenase that catalyses the fourth and final step of L-carnitine biosynthesis, converting gamma-butyrobetaine into L-carnitine. Biallelic BBOX1 variants block that final step, producing the characteristic biochemical pair of low plasma free and total L-carnitine together with markedly elevated plasma and urinary gamma-butyrobetaine, in the presence of a normal renal fractional excretion of carnitine - the feature that separates this disorder from SLC22A5-related systemic primary carnitine deficiency, where carnitine is lost through the kidney. Because carnitine is required for the carnitine shuttle that carries long-chain fatty acids into the mitochondrion, the resulting phenotype in the three reported patients is dominated by myopathic features (muscle weakness, exercise intolerance, fatigability), with neurodevelopmental (motor and speech delay, learning difficulty, autism) and late-onset psychiatric (psychosis, anxiety) manifestations also reported. Oral L-carnitine normalises circulating carnitine and improved muscle weakness and fatigability in the one patient in whom the response was documented, but does not lower gamma-butyrobetaine. Two caveats are curated explicitly rather than smoothed over. First, the genotype-phenotype relationship is not settled: an earlier patient homozygous for a 221 kb 11p14.2 deletion removing BBOX1 entirely had only a borderline-low free carnitine and none of the classic carnitine-deficiency manifestations, and homozygous predicted-truncating BBOX1 alleles are present in gnomAD. Second, the causal support for the disease mechanism rests substantially on a C. elegans gbh-1 model, in which the worm allele modelling one of the two patient variants (p.Asp59Gly) behaved like wild type.

Ask OpenScientist

Ask a research question about BBOX1-Related Carnitine Biosynthesis Deficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
15
Phenotypes
1
Hypotheses
3
Gaps
21
Pathograph
1
Genes
3
Variants
1
Medical Actions
2
Models
👪

Inheritance

1
Autosomal recessive HP:0000007
Autosomal recessive inheritance. Two affected siblings in family 1 carry the same compound heterozygous pair, one variant inherited from each unaffected parent; the proband in family 2 is homozygous for a third variant.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"revealed two compound heterozygous variants in BBOX1: NM_003986.3:c.176A>G (p.Asp59Gly) paternally inherited, and NM_003986.3:c.675delA (p.Gly227Valfs*6) maternally inherited"
Biparental inheritance of two different BBOX1 alleles in an affected proband establishes a recessive mechanism.
◈

Mechanistic Hypotheses

1
Gamma-butyrobetaine is independently toxic, not merely a marker
gamma_butyrobetaine_toxicity EMERGING
Evidence balance 1 support
Under this model the accumulated substrate contributes to disease in its own right, in parallel with the carnitine deficit, plausibly by competing with carnitine for cellular uptake and so deepening the intracellular deficiency. The evidence is a C. elegans exposure experiment in which millimolar gamma-butyrobetaine killed gbh-1 null and functionally null embryos even on carnitine-producing bacteria, plus the clinical observation that gamma-butyrobetaine stays elevated on L-carnitine treatment. It is curated as EMERGING rather than canonical because the transporter-competition step is labelled presumed by the authors, the lethality data are invertebrate, and no human outcome has been shown to track gamma-butyrobetaine level. It matters therapeutically: if true, normalising carnitine alone would leave part of the disease untreated.
Pathograph links
Gamma-Butyrobetaine Accumulation -> Carnitine Transport Inhibition by Gamma-Butyrobetaine INDIRECT UNKNOWN INTERMEDIATES Proposed independent contribution of the accumulated substrate, by chemical toxicity or by competition with carnitine for cellular uptake. Curated as a hypothesis arm because the mechanism is explicitly presumptive and the supporting lethality data are from C. elegans.
Carnitine Transport Inhibition by Gamma-Butyrobetaine -> Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation INDIRECT UNKNOWN INTERMEDIATES If gamma-butyrobetaine competes with carnitine for cellular uptake, the intracellular carnitine available to the shuttle falls further than circulating levels alone would predict.
Show evidence (1 reference)
PMID:41022783 SUPPORT INDIRECT Model Organism
"Translating results from the nematode model to human disease further allows the assumption that both L-carnitine deficiency and accumulation of γ-BB play an independent but synergistic role in the pathogenesis of human BBOX1 deficiency."
States the two-arm hypothesis and, in the authors' own hedging, its status as an assumption carried over from the worm.
?

Discussions and Knowledge Gaps

3
Does biallelic loss of BBOX1 reliably cause clinical disease, or is the myopathic and neuropsychiatric phenotype dependent on modifiers, dietary carnitine intake, or ascertainment?
KNOWLEDGE GAP OPEN bbox1_genotype_phenotype_penetrance
Attached to
pathophysiology#BBOX1 Loss of Function pathophysiology#Systemic L-Carnitine Deficiency
Three lines of evidence pull against a simple fully-penetrant model. An individual homozygous for a 221 kb 11p14.2 deletion removing BBOX1 outright had only a borderline-low free carnitine, a normal acylcarnitine-to-free-carnitine ratio and none of the classic carnitine-deficiency manifestations, and the authors of that report concluded that dietary intake and renal reabsorption suffice for carnitine homeostasis. Homozygous predicted-truncating BBOX1 alleles are present in gnomAD. And the family 1 patients are compound heterozygous for an allele that retains function in the orthologous worm assay. Since the biosynthetic arm is only one of three inputs to carnitine homeostasis, dietary carnitine intake is a plausible modifier that no reported case controls for. Resolving this matters for whether BBOX1 should be added to metabolic gene panels and for how a homozygous truncating variant found incidentally should be reported. A fourth line, and the one most specific to this cohort: two of the three patients carry additional variants in fatty-acid-oxidation genes, and the causal chain proposed here runs through carnitine-dependent fatty acid oxidation, so those variants are candidate confounders rather than incidental findings. Patient 3 is homozygous for CPT1A NM_001876.4:c.1436C>T (p.Pro479Leu), which the authors state is associated with a mild form of carnitine palmitoyl transferase I deficiency and puts homozygotes at risk of fasting hypoglycemia; the same authors note that patient 3's symptoms have not been associated with that variant, so this is a confound they considered and argued against rather than one they overlooked. The variant is common in the Indigenous Background Variant Library at roughly 11% allele frequency, which matters for how much weight a rarity-based pathogenicity argument can carry in this population. Patient 1 additionally carries a heterozygous ACADL frameshift (NM_001608.4:c.1018_1019del, p.His340Tyrfs*16) and an RYR1 variant of uncertain significance (NM_000540.3:c.10171G>A, p.Glu3391Lys) - the first in long-chain acyl-CoA dehydrogenase, immediately downstream of the carnitine shuttle, and the second in a gene whose phenotypes include exercise intolerance and myopathy, which are this entry's most consistent features. Neither is called causal by the authors, and a single heterozygous ACADL allele is not expected to be, but in a three-patient cohort they bound how confidently any individual feature can be attributed to BBOX1 alone.
Show evidence (5 references)
PMID:24986124 REFUTE Human Clinical
"This condition results in mildly decreased free carnitine level, but not in clinical manifestations characteristic of carnitine deficiency disorders, suggesting that dietary carnitine intake and renal reabsorption are sufficient to carnitine homeostasis."
A complete BBOX1 deletion produced no classic carnitine-deficiency phenotype, arguing against obligate clinical consequence.
PMID:41022783 SUPPORT Human Clinical
"have been found in homozygous individuals in the population database gnomAD, posing the question of whether these individuals may have milder phenotypes, possibly due to modifier effects"
The authors themselves raise unaffected or mildly affected homozygous truncating carriers as an open question.
PMID:41022783 SUPPORT DIRECT Human Clinical
"It is associated with a mild form of carnitine palmitoyl transferase I deficiency, putting homozygous individuals at risk for fasting hypoglycemia"
Establishes that patient 3's homozygous CPT1A p.Pro479Leu genotype is itself a fatty-acid-oxidation disorder allele, which is why it is treated here as a candidate confounder of that patient's phenotype.
+ 2 more references
Are the neurodevelopmental and psychiatric features mechanistically caused by BBOX1 deficiency, and if so through what route - brain carnitine depletion, gamma-butyrobetaine toxicity, or neither?
KNOWLEDGE GAP OPEN bbox1_neuropsychiatric_attribution
Attached to
phenotypes#Autism Spectrum Disorder phenotypes#Psychosis pathophysiology#Gamma-Butyrobetaine Accumulation
The report singles out neurodevelopmental and psychiatric manifestations as specific to BBOX1 deficiency, in contrast to the myopathic features it shares with SLC22A5 disease. But no mechanistic route is curated here because none has been demonstrated: the supporting arguments offered are an association of BBOX1 polymorphisms with schizophrenia susceptibility and downregulation of BBOX1 in a mouse schizophrenia model, neither of which establishes that carnitine depletion or substrate accumulation in the brain produces these features. The cohort is three patients from two families with heterogeneous presentations - autism and learning difficulty in one, psychosis in another, anxiety in two - which is not enough to separate a causal effect from coincidence. TMLHE deficiency at the first step of the same pathway carries a comparable and similarly unresolved autism association, so this is a pathway-level question rather than a BBOX1-specific one.
Show evidence (1 reference)
PMID:41022783 SUPPORT INDIRECT Human Clinical
"additional neurodevelopmental and psychiatric manifestations seem to be specifically related to BBOX1 deficiency"
States the attribution claim in the hedged form that makes it a knowledge gap rather than a curated mechanism.
Can the C. elegans gbh-1 model support causal claims about human BBOX1 disease when the worm equivalent of the patients' compound-heterozygous genotype is phenotypically normal?
HUMAN MODEL MISMATCH OPEN bbox1_worm_model_translational_validity
Attached to
animal_models#gbh-1 patient-allele knock-in C. elegans pathophysiology#Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
The worm model carries most of the causal weight in this first report: it is where the biosynthetic block, the substrate accumulation and the carnitine rescue are demonstrated. Yet the strain modelling p.Asp59Gly behaves as wild type on every assay, and the trans-heterozygote reproducing the family 1 genotype shows no lethality even under starvation, so the model does not reproduce the disease state of the two most fully characterised patients. The human data are also partly discordant with a downstream fatty-acid-oxidation block: patient 1's palmitate-loaded fibroblasts had a normal acylcarnitine profile, whereas the worm strains lose the acylcarnitine pool entirely. This is a mismatch of translational validity rather than an absence of evidence - the experiments were done, and they do not line up - so it is curated as HUMAN_MODEL_MISMATCH. Resolving it needs a mammalian model or a human tissue-level measurement of carnitine-dependent fatty acid oxidation.
Proposed experiments
Human muscle carnitine and fatty-acid-oxidation flux in a BBOX1 patient
exp_bbox1_muscle_fao_flux
Measure muscle total and free carnitine plus long-chain fatty acid oxidation flux in a biopsy from a molecularly confirmed patient sampled before starting or after a supervised washout of L-carnitine, against matched controls. This is the measurement that would put the human arm of the shuttle step on direct evidence rather than on inference from carnitine's known role, and it would also address the discordance with the normal fibroblast acylcarnitine profile, since fibroblasts are not the tissue in which the phenotype manifests.
Would support
pathophysiology#Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
Would refute
pathophysiology#Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
Supporting outcome
  • Reduced muscle carnitine content with reduced long-chain fatty acid oxidation flux relative to controls, correcting on resupplementation, would establish the shuttle step in human tissue.
Refuting outcome
  • Normal muscle carnitine content and normal oxidation flux despite low plasma carnitine would locate the myopathy outside the carnitine shuttle and force a different account of the muscle phenotype.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"By contrast, gbh-1(D72G) mutants displayed wild-type embryonic viability under all conditions tested"
The patient-derived allele carried by both family 1 siblings is functionally silent in the model, which is the mismatch.
⚙

Pathophysiology

8
BBOX1 Loss of Function
Biallelic BBOX1 variants reduce or abolish the activity of gamma-butyrobetaine hydroxylase, the cytosolic dimeric dioxygenase that catalyses the terminal hydroxylation converting gamma-butyrobetaine to L-carnitine. Two missense alleles (p.Asp59Gly, p.Gly263Arg) and one frameshift allele (p.Gly227Valfs*6, predicted to remove 40% of the C-terminus) have been reported.
BBOX1 hgnc:964 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves BBOX1 (hgnc:964). hgnc:964 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context BBOX1 hgnc:964 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns BBOX1 (hgnc:964). hgnc:964 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: GERMLINE zygosity: COMPOUND_HETEROZYGOUS functional_impact_category: LOSS_OF_FUNCTION
Family 1 (two affected siblings) is compound heterozygous for NM_003986.3:c.176A>G (p.Asp59Gly) and NM_003986.3:c.675delA (p.Gly227Valfs*6); the family 2 proband is homozygous for NM_003986.3:c.787G>A (p.Gly263Arg).
gamma-butyrobetaine dioxygenase activity GO:0008336 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves gamma-butyrobetaine dioxygenase activity (GO:0008336), qualified as loss of function. GO:0008336 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
Animal models
gbh-1 patient-allele knock-in C. elegans Caenorhabditis elegans partially recapitulates Two of the three patient alleles behave as functional nulls in the worm, which is the functional evidence supporting their pathogenicity; the third does not.
Downstream
Blocked Final Step of Endogenous L-Carnitine Biosynthesis Loss of gamma-butyrobetaine hydroxylase activity removes the only enzyme that converts gamma-butyrobetaine to L-carnitine, so the biosynthetic pathway terminates one step short of its product.
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"Gamma-butyrobetaine hydroxylase (BBOX1) catalyses the last step of carnitine biosynthesis, converting γ-butyrobetaine (γ-BB) into L-carnitine."
Establishes the enzymatic step that BBOX1 catalyses and therefore what is lost.
PMID:41022783 SUPPORT Human Clinical
"The frameshift variant NM_003986.3:c.675delA (p.Gly227Valfs*6) (family 1) leads to a premature stop codon and is predicted to code for a truncated protein of 231 amino acids (40% of the C-terminus sequence removed)."
Characterises the frameshift allele as a predicted loss-of-function change.
Blocked Final Step of Endogenous L-Carnitine Biosynthesis
Endogenous L-carnitine synthesis proceeds in four enzymatic steps from 6-N-trimethyllysine and takes place mainly in liver, brain and kidney. With BBOX1 inactive the pathway is blocked at the final step: metabolites upstream of gamma-butyrobetaine are essentially unchanged while the immediate substrate accumulates and the product is not made. This selective, single-step blockade is what the C. elegans metabolomics demonstrates directly.
hepatocyte CL:0000182 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hepatocyte (CL:0000182). CL:0000182 is a cell type from the Cell Ontology.
carnitine biosynthetic process GO:0045329 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased carnitine biosynthetic process (GO:0045329). GO:0045329 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
gbh-1 null C. elegans Caenorhabditis elegans recapitulates Complete loss of the orthologous enzyme reproduces the selective terminal block: no L-carnitine, accumulated gamma-butyrobetaine, unchanged upstream precursors.
Downstream
Gamma-Butyrobetaine Accumulation The unconverted substrate of the blocked reaction accumulates in plasma and urine.
Systemic L-Carnitine Deficiency Loss of the endogenous synthetic contribution to carnitine homeostasis lowers circulating free and total carnitine.
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"Endogenous synthesis of L-carnitine occurs mainly in the liver, brain, and kidneys in a four-step enzymatic pathway, with 6-N-trimethyllysine (TML) as the initial substrate."
Locates the blocked pathway anatomically and defines its step structure.
PMID:41022783 SUPPORT Model Organism
"the absence of significant changes in other metabolites confirms that the loss of GBH-1 selectively impacts the L-carnitine biosynthesis pathway"
Worm metabolomics shows the lesion is confined to this pathway rather than perturbing metabolism broadly.
Gamma-Butyrobetaine Accumulation
Plasma and urinary gamma-butyrobetaine rise well above the reference interval and, unlike the carnitine deficit, are not corrected by L-carnitine supplementation - indicating that carnitine biosynthesis in this disorder is not subject to end-product feedback control. The accumulated substrate is the disorder's specific diagnostic marker, distinguishing it both from carnitine transporter defects and from TMLHE deficiency at the first step of the same pathway.
Gamma-butyrobetaine is independently toxic, not merely a marker
Downstream
Carnitine Transport Inhibition by Gamma-Butyrobetaine Proposed independent contribution of the accumulated substrate, by chemical toxicity or by competition with carnitine for cellular uptake. Curated as a hypothesis arm because the mechanism is explicitly presumptive and the supporting lethality data are from C. elegans. Gamma-butyrobetaine is independently toxic, not merely a marker
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"Measurement of L-carnitine biosynthesis intermediates revealed elevated γ-BB levels in plasma and urine"
Documents the accumulation of the blocked reaction's substrate in a patient.
PMID:41022783 SUPPORT Human Clinical
"the degree of γ-BB accumulation in the plasma remained unchanged upon L-carnitine supplementation. This finding suggests that there is no end product-controlled L-carnitine synthesis in BBOX1 deficiency"
Establishes that the substrate accumulation persists on treatment and is not feedback-regulated.
Carnitine Transport Inhibition by Gamma-Butyrobetaine
Hypothesised second pathogenic arm in which accumulated gamma-butyrobetaine is itself harmful rather than merely a marker of the block. In C. elegans, exposure of gbh-1 loss-of-function strains to millimolar gamma-butyrobetaine caused complete embryonic lethality even on carnitine-producing bacteria, which is the observation the toxicity proposal rests on. The suggested mechanism - competitive inhibition of the carnitine transporter, which would deepen the intracellular carnitine deficit - has not been demonstrated directly in either system.
Gamma-butyrobetaine is independently toxic, not merely a marker
carnitine transmembrane transport GO:1902603 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased carnitine transmembrane transport (GO:1902603). GO:1902603 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
gbh-1 null C. elegans Caenorhabditis elegans perturbs Exogenous gamma-butyrobetaine exposure is used as a direct perturbation to ask whether the accumulated substrate is harmful independently of the carnitine deficit; millimolar exposure was lethal to the null and functionally null strains on carnitine-replete bacteria.
Downstream
Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation If gamma-butyrobetaine competes with carnitine for cellular uptake, the intracellular carnitine available to the shuttle falls further than circulating levels alone would predict. Gamma-butyrobetaine is independently toxic, not merely a marker
Show evidence (2 references)
PMID:41022783 SUPPORT Model Organism
"Exposure to 1 mM γ-BB resulted in total embryonic lethality in the gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) mutants"
Provides the experimental basis for treating accumulated gamma-butyrobetaine as independently harmful.
PMID:41022783 SUPPORT INDIRECT Model Organism
"Presumed mechanisms of toxicity could be chemical or by competitive inhibition of the carnitine transporter, which would further aggravate the intracellular carnitine deficiency."
States the proposed transport-competition mechanism, which the authors label presumed rather than demonstrated.
Systemic L-Carnitine Deficiency
Free and total L-carnitine are persistently low in serum and dried blood spots. Critically, the renal fractional excretion of carnitine is normal, so the deficiency is one of failed production rather than of renal wasting; this was used clinically to exclude SLC22A5 transporter deficiency in the index patients. Loss of the biosynthetic arm alone is sufficient to lower circulating carnitine because dietary intake and tubular reabsorption do not fully compensate in these individuals.
carnitine metabolic process GO:0009437 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased carnitine metabolic process (GO:0009437). GO:0009437 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation Carnitine is the obligate carrier for the mitochondrial import of long-chain fatty acids, so a systemic carnitine deficit limits shuttle flux.
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"L-carnitine transporter and fatty acid oxidation-related L-carnitine deficiency were ruled out by normal renal excretion fraction of L-carnitine"
Establishes that the carnitine deficit is biosynthetic rather than a transporter or renal-wasting defect.
PMID:41022783 SUPPORT Human Clinical
"Biochemical genetic workup showed persistently low free carnitine levels both on dried bloodspots and in serum, in the presence of normal renal L-carnitine fractional excretion"
Documents the same biochemical signature independently in the second family.
Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
With less carnitine available, the carnitine shuttle carries fewer activated long-chain fatty acids across the inner mitochondrial membrane and beta-oxidation flux falls. The C. elegans model makes this consequence concrete: acylcarnitine species from C2 to C20 are undetectable in the null and functionally null strains. Note that the human patients were not shown to have a cellular fatty-acid-oxidation defect - patient 1 had a normal acylcarnitine profile in palmitate-loaded fibroblasts - so the human arm of this step is an inference from carnitine's known role rather than a direct measurement.
carnitine shuttle GO:0006853 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased carnitine shuttle (GO:0006853). GO:0006853 is a biological process from the Gene Ontology. ↓ DECREASED fatty acid beta-oxidation GO:0006635 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased fatty acid beta-oxidation (GO:0006635). GO:0006635 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Skeletal Muscle Energy Deficit Skeletal muscle depends on fatty acid oxidation for sustained energy supply, so reduced shuttle flux presents as exercise intolerance, fatigability and weakness.
Impaired Hepatic Ketogenesis During Fasting The same sentence that establishes carnitine's role in muscle energy metabolism names hepatic ketogenesis during fasting as the other process that depends on it, so reduced shuttle flux is expected to blunt fasting ketogenesis as well.
Cardiomyopathy Cardiac muscle is named alongside skeletal muscle as dependent on carnitine-mediated fatty acid oxidation for energy, which is the route by which the index patient's transient cardiomyopathy is attributed to this step. One of three patients was affected and it resolved, so this link is weaker than the skeletal muscle one.
Show evidence (4 references)
PMID:41022783 SUPPORT INDIRECT Human Clinical
"L-carnitine is essential for transporting long-chain fatty acids into the mitochondria for β-oxidation, which is essential for cardiac and skeletal muscle energy metabolism and hepatic ketogenesis during fasting periods."
States carnitine's obligate role in mitochondrial long-chain fatty acid import, from which reduced shuttle flux under carnitine deficiency follows.
PMID:11802770 SUPPORT INDIRECT Other
"Carnitine is indispensable for energy metabolism, since it enables activated fatty acids to enter the mitochondria, where they are broken down via beta-oxidation."
Independent review support for the carnitine-dependence of mitochondrial fatty acid oxidation.
PMID:41022783 SUPPORT Model Organism
"The acylcarnitine spectrum is markedly absent in gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) worms, as reflected by non-detectable levels across these mutants."
Demonstrates loss of the acylcarnitine pool, the direct biochemical evidence that shuttle substrate handling collapses.
+ 1 more reference
Impaired Hepatic Ketogenesis During Fasting
Carnitine-dependent fatty acid oxidation supplies the substrate for hepatic ketone body production, which is what sustains the fasting state once glycogen is exhausted. In the index patient this arm presented in infancy as episodes of irritability and lethargy during prolonged fasting that resolved on feeding. Note what was not shown: ketone bodies were not measured during those episodes, and the report disagrees with itself about whether hypoglycemia accompanied them, so this node is an inference from carnitine's established role plus a fasting-responsive clinical picture rather than a measured ketogenic defect.
hepatic ketone body biosynthesis GO:0046951 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased hepatic ketone body biosynthesis, annotated with ketone body biosynthetic process (GO:0046951). GO:0046951 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Fasting Intolerance Failure to sustain fasting metabolism presents clinically as intolerance of prolonged fasting, relieved by feeding.
Episodic Infantile Lethargy and Irritability The infantile episodes are the symptomatic expression of the fasting energy deficit, and remitted on feeding.
Show evidence (2 references)
PMID:41022783 SUPPORT INDIRECT BACKGROUND Human Clinical
"L-carnitine is essential for transporting long-chain fatty acids into the mitochondria for β-oxidation, which is essential for cardiac and skeletal muscle energy metabolism and hepatic ketogenesis during fasting periods."
The paper's introduction states the dependence of fasting hepatic ketogenesis on carnitine-mediated fatty acid import, from which this node follows. Graded INDIRECT because it establishes the pathway rather than measuring it in these patients.
PMID:41022783 SUPPORT INDIRECT Human Clinical
"Patient 1 presented first during his infancy with episodes of irritability and lethargy associated with prolonged fasting that were responsive to feeding."
A fasting-triggered, feeding-responsive symptom pattern is the clinical correlate of a failure to sustain the fasting state, though ketones were not measured during the episodes.
Skeletal Muscle Energy Deficit
Muscle weakness, exercise intolerance and fatigability were present in all three reported patients and are the most consistent clinical feature of the disorder. In patient 1 the weakness was trunk- and proximal-predominant and accompanied by muscle wasting, ptosis and swallowing difficulty; muscle biopsy showed type 1 fibre predominance with normal mitochondrial morphology, respiratory chain enzyme activity and Gomori trichrome staining, so no structural myopathy or storage disease was demonstrated.
skeletal muscle fiber CL:0008002 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves skeletal muscle fiber (CL:0008002). CL:0008002 is a cell type from the Cell Ontology.
Animal models
gbh-1 patient-allele knock-in C. elegans Caenorhabditis elegans fails to recapitulate The worm strains carrying the family 1 compound-heterozygous genotype are phenotypically normal, and no strain reproduces the myopathic phenotype that defines the human disease; the readout available in this system is embryonic viability.
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"he developed fine motor coordination delay, swallowing difficulty with frequent choking, bilateral ptosis, as well as exercise intolerance, intermittent muscle soreness, and generalized muscle weakness affecting mainly his trunk and proximal muscles"
Documents the myopathic presentation in the index patient.
PMID:41022783 SUPPORT Human Clinical
"Myopathic, neurodevelopmental, and late-onset psychiatric manifestations are clinical hallmarks in our patients."
Summarises the myopathic component as a defining feature across the cohort.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for BBOX1-Related Carnitine Biosynthesis Deficiency Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

15
Cardiovascular 1
Cardiomyopathy FREQUENT HP:0001638 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild, transient cardiomyopathy, annotated with Cardiomyopathy (HP:0001638). HP:0001638 is a phenotype from the Human Phenotype Ontology.
Banded FREQUENT because one of three reported patients is 33%, inside the 30-79% band, not the 5-29% OCCASIONAL band. See the entry-level notes on the frequency convention: every single-patient finding here is banded the same way. With a cohort of three the band carries almost no information; it is recorded for consistency rather than as an estimate.
Show evidence (1 reference)
PMID:41022783 SUPPORT DIRECT Human Clinical
"He also developed a mild cardiomyopathy that resolved by the age of 18 years."
Documents the cardiomyopathy and its resolution in the index patient, which is the whole basis for this phenotype.
Digestive 1
Swallowing Difficulty FREQUENT Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"swallowing difficulty with frequent choking"
Documents dysphagia in the index patient.
Eye 1
Bilateral Ptosis FREQUENT HP:0000508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ptosis (HP:0000508). HP:0000508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"he developed fine motor coordination delay, swallowing difficulty with frequent choking, bilateral ptosis"
Documents ptosis in the index patient.
Musculoskeletal 1
Muscle Weakness VERY_FREQUENT HP:0001324 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Muscle weakness (HP:0001324). HP:0001324 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"At 4 years of age, she started having muscle weakness, exercise intolerance, and impaired gait."
Documents muscle weakness in the second affected sibling.
Nervous System 7
Episodic Infantile Lethargy and Irritability FREQUENT HP:0000737 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fasting-triggered episodes of lethargy and irritability, annotated with Irritability (HP:0000737). HP:0000737 is a phenotype from the Human Phenotype Ontology.
Bound to HP:0000737 Irritability, which captures only half of the episode. HP:0011973 "Paroxysmal lethargy" would capture the other half and drop the irritability; neither term covers the compound episode, and the slot takes one term. The preferred_term carries the full description.
Show evidence (1 reference)
PMID:41022783 SUPPORT DIRECT Human Clinical
"Patient 1 presented first during his infancy with episodes of irritability and lethargy associated with prolonged fasting that were responsive to feeding."
Documents the episodes, their fasting trigger, and their response to feeding, which is what ties them to the hepatic ketogenesis arm.
Motor Delay VERY_FREQUENT HP:0001270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"At 6 years, he developed fine motor coordination delay"
Documents fine motor delay in the index patient.
Speech and Language Delay FREQUENT Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"The patient presented at age 4 years with language delay, learning difficulties and was later diagnosed with autism spectrum disorder."
Documents speech delay and learning difficulty in the family 2 proband.
Autism Spectrum Disorder FREQUENT HP:0000717 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autism (HP:0000717). HP:0000717 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"was later diagnosed with autism spectrum disorder"
Documents the autism diagnosis in the family 2 proband.
Psychosis FREQUENT HP:0000709 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Psychosis (HP:0000709). HP:0000709 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"Since the age of 23 years, he has been seen for episodes of psychosis and one episode of ketamine-induced seizures."
Documents adult-onset psychosis in the index patient.
Anxiety FREQUENT HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"As a young adult, she developed severe anxiety."
Documents severe anxiety in the second affected sibling.
Migraine FREQUENT HP:0002076 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Migraine (HP:0002076). HP:0002076 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"Patient 2 was seen during her childhood for migraine headaches, coordination difficulty, and dyslexia, requiring assistance at school."
Documents migraine in the second affected sibling.
Constitutional 3
Exercise Intolerance VERY_FREQUENT HP:0003546 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exercise intolerance (HP:0003546). HP:0003546 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"There was a history of fatigability and intolerance to physical exercise."
Documents exercise intolerance in the family 2 proband.
Fatigability VERY_FREQUENT Fatigue HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"There was a history of fatigability and intolerance to physical exercise."
Documents fatigability as a presenting complaint.
Muscle Soreness FREQUENT Myalgia HP:0003326 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myalgia (HP:0003326). HP:0003326 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"as well as exercise intolerance, intermittent muscle soreness, and generalized muscle weakness affecting mainly his trunk and proximal muscles"
Documents intermittent muscle soreness alongside the other myopathic features in the index patient.
Other 1
Fasting Intolerance FREQUENT
Left unbound deliberately. HPO has no term for fasting intolerance: a search of the HP label cache for "fasting" returns only HP:0003162 "Fasting hypoglycemia", and binding that would assert hypoglycemia, which is the one thing this report contradicts itself about. The prose states "Hypoglycemia was not documented" for this patient while Table 1 marks hypoglycemia "+" in his column. The prose side is carried as a REFUTE evidence item above; the Table 1 side is recorded here rather than as a snippet, because that table's columns are separated by em spaces and a single cell is not a quotable propositional sentence. Either way the disagreement stays visible instead of being settled by the choice of ontology term.
Show evidence (2 references)
PMID:41022783 SUPPORT DIRECT Human Clinical
"Patient 1 presented first during his infancy with episodes of irritability and lethargy associated with prolonged fasting that were responsive to feeding."
The prose sentence that makes the claim: symptoms tied to prolonged fasting and relieved by feeding, which is what fasting intolerance names. Table 1 records the same finding as "Fasting intolerance+ (infancy)" for patient 1 and absent in patients 2 and 3, but that cell is not quoted here - the table's columns are separated by em spaces and do not survive text extraction as a readable row.
PMID:41022783 REFUTE DIRECT Human Clinical
"Hypoglycemia was not documented, and symptoms improved as he reached childhood."
The prose denies documented hypoglycemia in the same patient whose Table 1 column marks it present. Carried as a REFUTE item against the hypoglycemic reading of these episodes, so the report's internal disagreement is curated rather than silently resolved.
🧬

Genetic Associations

1
BBOX1
Gene: BBOX1 hgnc:964 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BBOX1 (hgnc:964). hgnc:964 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Autosomal recessive
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"revealed a homozygous variant of uncertain significance in BBOX1 NM_003986.3:c.787G>A (p.Gly263Arg)"
Documents the third disease allele, homozygous in the family 2 proband.
PMID:41022783 SUPPORT Human Clinical
"suggesting that it may be a founder variant of community significance"
Records the population-frequency caveat attached to the p.Gly263Arg allele.
Variants (3)
NM_003986.3:c.176A>G (p.Asp59Gly)
Paternally inherited missense allele in family 1, predicted damaging by SIFT, PolyPhen-2 and CADD. The equivalent C. elegans allele retained normal function, so this allele is best regarded as hypomorphic.
NM_003986.3:c.675delA (p.Gly227Valfs*6)
Maternally inherited frameshift allele in family 1, predicted to truncate the protein at 231 residues.
NM_003986.3:c.787G>A (p.Gly263Arg)
Homozygous missense allele in the family 2 proband; present at about 1% in the Indigenous Background Variant Library and possibly a founder variant.
💊

Medical Actions

1
Oral L-carnitine supplementation
Action: L-carnitine supplementationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is L-carnitine supplementation, annotated with Nutritional Support (NCIT:C15433). NCIT:C15433 is a clinical intervention from the NCI Thesaurus. Ontology label: Nutritional Support NCIT:C15433
Agent: levocarnitine CHEBI:16347 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses levocarnitine, annotated with (R)-carnitine (CHEBI:16347). CHEBI:16347 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Oral L-carnitine at 50-100 mg/kg/day normalised serum free carnitine in the family 2 proband and was accompanied by improvement in muscle weakness and fatigability. It does not lower gamma-butyrobetaine, so it addresses only one of the two proposed pathogenic arms. Evidence is a single documented clinical response, and that patient was subsequently lost to follow-up, so durability is unknown.
Mechanism Target:
RESTORES Systemic L-Carnitine Deficiency — Exogenous L-carnitine bypasses the blocked biosynthetic step and restores circulating carnitine, which is the arm of the mechanism it can reach.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"normalized serum free L-carnitine levels and improved fatigability and muscle weakness"
Documents biochemical correction and symptomatic improvement on supplementation.
Show evidence (2 references)
PMID:41022783 SUPPORT Human Clinical
"Treatment with L-carnitine resulted in the correction of L-carnitine deficiency in all our patients."
Establishes that supplementation corrects the carnitine deficit across the cohort.
PMID:41022783 REFUTE Human Clinical
"while the degree of γ-BB accumulation in the plasma remained unchanged upon L-carnitine supplementation"
Shows the treatment leaves gamma-butyrobetaine accumulation untouched, so it is not a complete correction of the biochemical phenotype.
🔬

Biochemical Markers

3
Plasma free and total L-carnitine (DECREASED)
Context: Persistently low free and total L-carnitine in serum and dried blood spots is the finding that brings these patients to metabolic attention. On its own it is not discriminating - it is shared with SLC22A5 transporter deficiency and with secondary carnitine depletion - so it must be paired with a normal renal fractional excretion and an elevated gamma-butyrobetaine to point at BBOX1.
Pathograph Readouts
Readout Of Systemic L-Carnitine Deficiency Negative Diagnostic
Low circulating free carnitine is the direct circulating readout of the systemic carnitine deficit.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"Biochemical genetic workup revealed persistently low levels of serum free carnitine."
Documents the low circulating carnitine that defines the biochemical phenotype.
Plasma and urinary gamma-butyrobetaine (INCREASED)
Context: Elevated gamma-butyrobetaine, the substrate of the blocked reaction, is the disorder-specific marker. Reported plasma values in the two patients measured before supplementation were 5.50 and 13.20 umol/L against a 0.3-1.4 umol/L reference interval, and the elevation persisted during L-carnitine treatment. It is measured in specialised laboratories rather than on a routine acylcarnitine panel, which is why the diagnosis is easy to miss.
Pathograph Readouts
Readout Of Gamma-Butyrobetaine Accumulation Positive Diagnostic
Plasma and urinary gamma-butyrobetaine directly report accumulation of the unconverted substrate upstream of the enzymatic block.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"showing elevation of γ-BB in plasma (Table 1) and urine (data not shown) while plasma L-carnitine levels were within the normal range"
Shows that gamma-butyrobetaine stays elevated even when supplementation has normalised carnitine, making it the more robust marker.
Renal fractional excretion of carnitine (NORMAL)
Context: A normal fractional excretion of carnitine (below 5%) is the discriminating negative finding. It excludes SLC22A5/OCTN2 transporter deficiency, in which carnitine is wasted in the urine, and so redirects the workup from transport to biosynthesis. All three reported patients had values between 0.7 and 2.9%.
Pathograph Readouts
Readout Of Systemic L-Carnitine Deficiency Present Absent Diagnostic
A normal value establishes that the carnitine deficit is not caused by renal wasting, which is what makes a biosynthetic defect the remaining explanation.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"She had low serum L-carnitine levels in the presence of a normal renal extraction fraction of carnitine"
Documents the normal fractional excretion alongside low carnitine in the second sibling.
📊

Prevalence

1
Worldwide
Cases In Literature Not yet documented
Three patients from two unrelated families constitute the entire reported cohort of molecularly and biochemically confirmed BBOX1 deficiency as of the 2025 first report. No population estimate exists. One earlier individual with a homozygous 11p14.2 deletion removing BBOX1 was described biochemically but without the gamma-butyrobetaine measurements that define the disorder.
Show evidence (1 reference)
PMID:41022783 SUPPORT Human Clinical
"We report 3 probands from two unrelated families with rare BBOX1 variants, L-carnitine deficiency, and elevated levels of plasma γ-BB"
Establishes the size of the reported cohort.
🐁

Animal Models

2
gbh-1 null C. elegans
CRISPR/Cas9 knockout of gbh-1, the C. elegans orthologue of BBOX1 (33% sequence identity, with the residues altered in the patients invariant across species). The strain has no L-carnitine, more than 50-fold elevated gamma-butyrobetaine and an absent acylcarnitine spectrum, and shows nutrition-dependent embryonic lethality that is fully rescued by exogenous L-carnitine. Its value is that the worm's exogenous carnitine supply can be controlled - an E. coli caiA mutant that cannot make carnitine was used to remove it - which is the manipulation that separates the biosynthetic defect from dietary compensation. Its limits are the obvious ones: an invertebrate, a null rather than a patient allele, and an embryonic-lethality readout that has no counterpart in the human phenotype.
Species
Caenorhabditis elegans
Genotype
gbh-1(ko), full deletion of the BBOX1-orthologue coding sequence
Genes
BBOX1 hgnc:964 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns BBOX1 (hgnc:964). hgnc:964 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:41022783
Pathograph links
Blocked Final Step of Endogenous L-Carnitine Biosynthesis recapitulates fidelity: moderate Complete loss of the orthologous enzyme reproduces the selective terminal block: no L-carnitine, accumulated gamma-butyrobetaine, unchanged upstream precursors.
Limitations: Invertebrate system with a null allele; the corresponding human patients are hypomorphic compound heterozygotes or homozygotes for a missense allele, and no human tissue measurement of the biosynthetic block exists.
Readouts
L-carnitine level by HPLC-MS
Direction: ABOLISHED
Interpretation: Undetectable L-carnitine is the direct product-side readout of the terminal block.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"L-carnitine is undetectable in gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) strains, indicating a disruption in its biosynthesis."
Reports the measured loss of product in the null and functionally null strains.
Gamma-butyrobetaine level by HPLC-MS
Direction: INCREASED
Interpretation: Substrate accumulation above 50-fold is the substrate-side readout of the same block.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"The gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) strains exhibited profound accumulation of γ-BB, with levels more than 50-fold above those seen in wild-type N2 nematodes"
Quantifies substrate accumulation in the model.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"we observed a lethal embryonic phenotype for the gbh-1 loss-of-function strains, which was rescued upon L-carnitine supplementation"
The carnitine rescue is what makes the model informative for the biosynthetic block rather than for gene loss in general.
Carnitine Transport Inhibition by Gamma-Butyrobetaine perturbs fidelity: low Exogenous gamma-butyrobetaine exposure is used as a direct perturbation to ask whether the accumulated substrate is harmful independently of the carnitine deficit; millimolar exposure was lethal to the null and functionally null strains on carnitine-replete bacteria.
Limitations: A millimolar external exposure is far above the low-micromolar plasma elevations seen in patients, the readout is embryonic viability rather than carnitine uptake, and the proposed transporter-competition step was not measured.
Readouts
Embryonic hatch rate under gamma-butyrobetaine exposure
Direction: DECREASED
Interpretation: Loss of viability on carnitine-replete food is the observation that motivates an independent toxicity arm.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"A complete F1 embryonic lethality for gbh-1(ko), gbh-1(G247Vfs6), and gbh-1(G283R) worms at a 1 mM concentration of γ-butyrobetaine"
Reports the exposure result underlying the toxicity hypothesis.
Show evidence (1 reference)
PMID:41022783 SUPPORT INDIRECT Model Organism
"This pronounced vulnerability, even in the presence of the carnitine-producing E coli strain that served as a nutritional source, points to primary γ-BB toxicity."
The authors' own interpretation of the perturbation as evidence for primary substrate toxicity.
gbh-1 patient-allele knock-in C. elegans
CRISPR/Cas9 knock-in strains carrying worm equivalents of the three patient alleles. G283R and G247Vfs*6 genocopy the null. D72G, the equivalent of the p.Asp59Gly allele that both family 1 siblings carry, has normal embryonic viability, normal L-carnitine and only a roughly 2-fold gamma-butyrobetaine rise, and worms carrying D72G in trans with the frameshift allele - the actual patient genotype - showed no lethality at all.
Species
Caenorhabditis elegans
Genotype
gbh-1(D72G), gbh-1(G283R) and gbh-1(G247Vfs*6) knock-in strains modelling p.Asp59Gly, p.Gly263Arg and p.Gly227Valfs*6
Genes
BBOX1 hgnc:964 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns BBOX1 (hgnc:964). hgnc:964 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:41022783
Pathograph links
BBOX1 Loss of Function partially recapitulates fidelity: moderate Two of the three patient alleles behave as functional nulls in the worm, which is the functional evidence supporting their pathogenicity; the third does not.
Limitations: Allele-level fidelity is uneven, and the compound-heterozygous genotype of the two family 1 patients produces no phenotype in this system.
Readouts
Embryonic hatch rate of patient-allele strains
Direction: DECREASED
Interpretation: Genocopying the knockout is the functional criterion used to call G283R and G247Vfs*6 pathogenic.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"gbh-1(G283R) and gbh-1(G247Vfs*6) genocopied the knockout, exhibiting nutrition-dependent embryonic lethality"
Establishes the functional-null behaviour of two patient alleles.
Show evidence (1 reference)
PMID:41022783 SUPPORT Model Organism
"These results strongly suggest that gbh-1(G283R) and gbh-1(G247Vfs*6) are functional alleles."
The authors' functional conclusion for the two alleles that behave as nulls.
Skeletal Muscle Energy Deficit fails to recapitulate fidelity: low The worm strains carrying the family 1 compound-heterozygous genotype are phenotypically normal, and no strain reproduces the myopathic phenotype that defines the human disease; the readout available in this system is embryonic viability.
Limitations: C. elegans body-wall muscle is not a model of human skeletal muscle physiology, no muscle-specific measurement was made, and the D72G/G247Vfs*6 trans-heterozygote - the genotype of the two most fully characterised patients - had no phenotype even under starvation. The model therefore supports the biochemical lesion but does not connect it to the clinical phenotype.
Show evidence (2 references)
PMID:41022783 SUPPORT Model Organism
"double-heterozygous-mutant worms carrying both the D72G and G247Vfs*6 alleles (modeling the two patients carrying the compound heterozygous variants) showed no embryonic lethality, even under prior starvation"
The patient genotype produces no phenotype in the model, which is the failure being recorded.
+ 1 more reference
{ }

Source YAML

click to show 
name: BBOX1-Related Carnitine Biosynthesis Deficiency
creation_date: "2026-08-31T00:00:00Z"
category: Mendelian
description: >-
  BBOX1-related L-carnitine biosynthesis deficiency is a very recently delineated
  autosomal recessive inborn error of the endogenous carnitine synthesis pathway.
  BBOX1 encodes gamma-butyrobetaine hydroxylase, the cytosolic dioxygenase that
  catalyses the fourth and final step of L-carnitine biosynthesis, converting
  gamma-butyrobetaine into L-carnitine. Biallelic BBOX1 variants block that final
  step, producing the characteristic biochemical pair of low plasma free and total
  L-carnitine together with markedly elevated plasma and urinary gamma-butyrobetaine,
  in the presence of a normal renal fractional excretion of carnitine - the feature
  that separates this disorder from SLC22A5-related systemic primary carnitine
  deficiency, where carnitine is lost through the kidney. Because carnitine is
  required for the carnitine shuttle that carries long-chain fatty acids into the
  mitochondrion, the resulting phenotype in the three reported patients is dominated
  by myopathic features (muscle weakness, exercise intolerance, fatigability), with
  neurodevelopmental (motor and speech delay, learning difficulty, autism) and
  late-onset psychiatric (psychosis, anxiety) manifestations also reported. Oral
  L-carnitine normalises circulating carnitine and improved muscle weakness and
  fatigability in the one patient in whom the response was documented, but does not
  lower gamma-butyrobetaine.

  Two caveats are curated explicitly rather than smoothed over. First, the
  genotype-phenotype relationship is not settled: an earlier patient homozygous for
  a 221 kb 11p14.2 deletion removing BBOX1 entirely had only a borderline-low free
  carnitine and none of the classic carnitine-deficiency manifestations, and
  homozygous predicted-truncating BBOX1 alleles are present in gnomAD. Second, the
  causal support for the disease mechanism rests substantially on a C. elegans
  gbh-1 model, in which the worm allele modelling one of the two patient variants
  (p.Asp59Gly) behaved like wild type.
synonyms:
- Gamma-butyrobetaine hydroxylase deficiency
- BBOX1 deficiency
- BBOX1-related L-carnitine biosynthesis deficiency
- Gamma-butyrobetaine dioxygenase deficiency
parents:
- Fatty Acid Oxidation Disorder
- Inborn Error of Metabolism
inheritance:
- name: Autosomal recessive
  description: >-
    Autosomal recessive inheritance. Two affected siblings in family 1 carry the
    same compound heterozygous pair, one variant inherited from each unaffected
    parent; the proband in family 2 is homozygous for a third variant.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "revealed two compound heterozygous variants in BBOX1: NM_003986.3:c.176A>G (p.Asp59Gly) paternally inherited, and NM_003986.3:c.675delA (p.Gly227Valfs*6) maternally inherited"
    explanation: Biparental inheritance of two different BBOX1 alleles in an affected proband establishes a recessive mechanism.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    Three patients from two unrelated families constitute the entire reported
    cohort of molecularly and biochemically confirmed BBOX1 deficiency as of the
    2025 first report. No population estimate exists. One earlier individual with a
    homozygous 11p14.2 deletion removing BBOX1 was described biochemically but
    without the gamma-butyrobetaine measurements that define the disorder.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 3 probands from two unrelated families with rare BBOX1 variants, L-carnitine deficiency, and elevated levels of plasma γ-BB"
    explanation: Establishes the size of the reported cohort.
pathophysiology:
- name: BBOX1 Loss of Function
  biological_scale: MOLECULAR
  description: >-
    Biallelic BBOX1 variants reduce or abolish the activity of gamma-butyrobetaine
    hydroxylase, the cytosolic dimeric dioxygenase that catalyses the terminal
    hydroxylation converting gamma-butyrobetaine to L-carnitine. Two missense
    alleles (p.Asp59Gly, p.Gly263Arg) and one frameshift allele
    (p.Gly227Valfs*6, predicted to remove 40% of the C-terminus) have been
    reported.
  gene:
    preferred_term: BBOX1
    term:
      id: hgnc:964
      label: BBOX1
  molecular_functions:
  - preferred_term: gamma-butyrobetaine dioxygenase activity
    term:
      id: GO:0008336
      label: gamma-butyrobetaine dioxygenase activity
    modifier: LOSS_OF_FUNCTION
  genetic_context:
    gene:
      preferred_term: BBOX1
      term:
        id: hgnc:964
        label: BBOX1
    zygosity: COMPOUND_HETEROZYGOUS
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
    description: >-
      Family 1 (two affected siblings) is compound heterozygous for
      NM_003986.3:c.176A>G (p.Asp59Gly) and NM_003986.3:c.675delA
      (p.Gly227Valfs*6); the family 2 proband is homozygous for
      NM_003986.3:c.787G>A (p.Gly263Arg).
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gamma-butyrobetaine hydroxylase (BBOX1) catalyses the last step of carnitine biosynthesis, converting γ-butyrobetaine (γ-BB) into L-carnitine."
    explanation: Establishes the enzymatic step that BBOX1 catalyses and therefore what is lost.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The frameshift variant NM_003986.3:c.675delA (p.Gly227Valfs*6) (family 1) leads to a premature stop codon and is predicted to code for a truncated protein of 231 amino acids (40% of the C-terminus sequence removed)."
    explanation: Characterises the frameshift allele as a predicted loss-of-function change.
  downstream:
  - target: Blocked Final Step of Endogenous L-Carnitine Biosynthesis
    causal_link_type: DIRECT
    description: >-
      Loss of gamma-butyrobetaine hydroxylase activity removes the only enzyme
      that converts gamma-butyrobetaine to L-carnitine, so the biosynthetic
      pathway terminates one step short of its product.
- name: Blocked Final Step of Endogenous L-Carnitine Biosynthesis
  biological_scale: MOLECULAR
  description: >-
    Endogenous L-carnitine synthesis proceeds in four enzymatic steps from
    6-N-trimethyllysine and takes place mainly in liver, brain and kidney. With
    BBOX1 inactive the pathway is blocked at the final step: metabolites upstream
    of gamma-butyrobetaine are essentially unchanged while the immediate substrate
    accumulates and the product is not made. This selective, single-step blockade
    is what the C. elegans metabolomics demonstrates directly.
  biological_processes:
  - preferred_term: carnitine biosynthetic process
    term:
      id: GO:0045329
      label: carnitine biosynthetic process
    modifier: DECREASED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Endogenous synthesis of L-carnitine occurs mainly in the liver, brain, and kidneys in a four-step enzymatic pathway, with 6-N-trimethyllysine (TML) as the initial substrate."
    explanation: Locates the blocked pathway anatomically and defines its step structure.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the absence of significant changes in other metabolites confirms that the loss of GBH-1 selectively impacts the L-carnitine biosynthesis pathway"
    explanation: Worm metabolomics shows the lesion is confined to this pathway rather than perturbing metabolism broadly.
  downstream:
  - target: Gamma-Butyrobetaine Accumulation
    causal_link_type: DIRECT
    description: >-
      The unconverted substrate of the blocked reaction accumulates in plasma and
      urine.
  - target: Systemic L-Carnitine Deficiency
    causal_link_type: DIRECT
    description: >-
      Loss of the endogenous synthetic contribution to carnitine homeostasis
      lowers circulating free and total carnitine.
- name: Gamma-Butyrobetaine Accumulation
  biological_scale: ORGANISM
  description: >-
    Plasma and urinary gamma-butyrobetaine rise well above the reference interval
    and, unlike the carnitine deficit, are not corrected by L-carnitine
    supplementation - indicating that carnitine biosynthesis in this disorder is
    not subject to end-product feedback control. The accumulated substrate is the
    disorder's specific diagnostic marker, distinguishing it both from carnitine
    transporter defects and from TMLHE deficiency at the first step of the same
    pathway.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Measurement of L-carnitine biosynthesis intermediates revealed elevated γ-BB levels in plasma and urine"
    explanation: Documents the accumulation of the blocked reaction's substrate in a patient.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the degree of γ-BB accumulation in the plasma remained unchanged upon L-carnitine supplementation. This finding suggests that there is no end product-controlled L-carnitine synthesis in BBOX1 deficiency"
    explanation: Establishes that the substrate accumulation persists on treatment and is not feedback-regulated.
  downstream:
  - target: Carnitine Transport Inhibition by Gamma-Butyrobetaine
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - gamma_butyrobetaine_toxicity
    description: >-
      Proposed independent contribution of the accumulated substrate, by chemical
      toxicity or by competition with carnitine for cellular uptake. Curated as a
      hypothesis arm because the mechanism is explicitly presumptive and the
      supporting lethality data are from C. elegans.
- name: Carnitine Transport Inhibition by Gamma-Butyrobetaine
  biological_scale: CELLULAR
  description: >-
    Hypothesised second pathogenic arm in which accumulated gamma-butyrobetaine is
    itself harmful rather than merely a marker of the block. In C. elegans,
    exposure of gbh-1 loss-of-function strains to millimolar gamma-butyrobetaine
    caused complete embryonic lethality even on carnitine-producing bacteria, which
    is the observation the toxicity proposal rests on. The suggested mechanism -
    competitive inhibition of the carnitine transporter, which would deepen the
    intracellular carnitine deficit - has not been demonstrated directly in either
    system.
  biological_processes:
  - preferred_term: carnitine transmembrane transport
    term:
      id: GO:1902603
      label: carnitine transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Exposure to 1 mM γ-BB resulted in total embryonic lethality in the gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) mutants"
    explanation: Provides the experimental basis for treating accumulated gamma-butyrobetaine as independently harmful.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Presumed mechanisms of toxicity could be chemical or by competitive inhibition of the carnitine transporter, which would further aggravate the intracellular carnitine deficiency."
    explanation: States the proposed transport-competition mechanism, which the authors label presumed rather than demonstrated.
  downstream:
  - target: Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - gamma_butyrobetaine_toxicity
    description: >-
      If gamma-butyrobetaine competes with carnitine for cellular uptake, the
      intracellular carnitine available to the shuttle falls further than
      circulating levels alone would predict.
- name: Systemic L-Carnitine Deficiency
  biological_scale: ORGANISM
  description: >-
    Free and total L-carnitine are persistently low in serum and dried blood spots.
    Critically, the renal fractional excretion of carnitine is normal, so the
    deficiency is one of failed production rather than of renal wasting; this was
    used clinically to exclude SLC22A5 transporter deficiency in the index
    patients. Loss of the biosynthetic arm alone is sufficient to lower circulating
    carnitine because dietary intake and tubular reabsorption do not fully
    compensate in these individuals.
  biological_processes:
  - preferred_term: carnitine metabolic process
    term:
      id: GO:0009437
      label: carnitine metabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "L-carnitine transporter and fatty acid oxidation-related L-carnitine deficiency were ruled out by normal renal excretion fraction of L-carnitine"
    explanation: Establishes that the carnitine deficit is biosynthetic rather than a transporter or renal-wasting defect.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biochemical genetic workup showed persistently low free carnitine levels both on dried bloodspots and in serum, in the presence of normal renal L-carnitine fractional excretion"
    explanation: Documents the same biochemical signature independently in the second family.
  downstream:
  - target: Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
    causal_link_type: DIRECT
    description: >-
      Carnitine is the obligate carrier for the mitochondrial import of long-chain
      fatty acids, so a systemic carnitine deficit limits shuttle flux.
- name: Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
  biological_scale: CELLULAR
  description: >-
    With less carnitine available, the carnitine shuttle carries fewer activated
    long-chain fatty acids across the inner mitochondrial membrane and
    beta-oxidation flux falls. The C. elegans model makes this consequence
    concrete: acylcarnitine species from C2 to C20 are undetectable in the null and
    functionally null strains. Note that the human patients were not shown to have
    a cellular fatty-acid-oxidation defect - patient 1 had a normal acylcarnitine
    profile in palmitate-loaded fibroblasts - so the human arm of this step is an
    inference from carnitine's known role rather than a direct measurement.
  biological_processes:
  - preferred_term: carnitine shuttle
    term:
      id: GO:0006853
      label: carnitine shuttle
    modifier: DECREASED
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
    modifier: DECREASED
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "L-carnitine is essential for transporting long-chain fatty acids into the mitochondria for β-oxidation, which is essential for cardiac and skeletal muscle energy metabolism and hepatic ketogenesis during fasting periods."
    explanation: States carnitine's obligate role in mitochondrial long-chain fatty acid import, from which reduced shuttle flux under carnitine deficiency follows.
  - reference: PMID:11802770
    reference_title: "Carnitine biosynthesis in mammals."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Carnitine is indispensable for energy metabolism, since it enables activated fatty acids to enter the mitochondria, where they are broken down via beta-oxidation."
    explanation: Independent review support for the carnitine-dependence of mitochondrial fatty acid oxidation.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The acylcarnitine spectrum is markedly absent in gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) worms, as reflected by non-detectable levels across these mutants."
    explanation: Demonstrates loss of the acylcarnitine pool, the direct biochemical evidence that shuttle substrate handling collapses.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "by demonstration of a normal acylcarnitine profile in cultured fibroblasts incubated with palmitic acid and L-carnitine"
    explanation: Patient fibroblasts loaded with palmitate showed no fatty-acid-oxidation defect, arguing against a cell-autonomous beta-oxidation block in the human disease.
  downstream:
  - target: Skeletal Muscle Energy Deficit
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Skeletal muscle depends on fatty acid oxidation for sustained energy supply,
      so reduced shuttle flux presents as exercise intolerance, fatigability and
      weakness.
  - target: Impaired Hepatic Ketogenesis During Fasting
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The same sentence that establishes carnitine's role in muscle energy
      metabolism names hepatic ketogenesis during fasting as the other process
      that depends on it, so reduced shuttle flux is expected to blunt fasting
      ketogenesis as well.
  - target: Cardiomyopathy
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Cardiac muscle is named alongside skeletal muscle as dependent on
      carnitine-mediated fatty acid oxidation for energy, which is the route by
      which the index patient's transient cardiomyopathy is attributed to this
      step. One of three patients was affected and it resolved, so this link is
      weaker than the skeletal muscle one.
- name: Impaired Hepatic Ketogenesis During Fasting
  biological_scale: TISSUE
  description: >-
    Carnitine-dependent fatty acid oxidation supplies the substrate for hepatic
    ketone body production, which is what sustains the fasting state once
    glycogen is exhausted. In the index patient this arm presented in infancy as
    episodes of irritability and lethargy during prolonged fasting that resolved
    on feeding. Note what was not shown: ketone bodies were not measured during
    those episodes, and the report disagrees with itself about whether
    hypoglycemia accompanied them, so this node is an inference from carnitine's
    established role plus a fasting-responsive clinical picture rather than a
    measured ketogenic defect.
  biological_processes:
  - preferred_term: hepatic ketone body biosynthesis
    term:
      id: GO:0046951
      label: ketone body biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "L-carnitine is essential for transporting long-chain fatty acids into the mitochondria for β-oxidation, which is essential for cardiac and skeletal muscle energy metabolism and hepatic ketogenesis during fasting periods."
    explanation: >-
      The paper's introduction states the dependence of fasting hepatic
      ketogenesis on carnitine-mediated fatty acid import, from which this node
      follows. Graded INDIRECT because it establishes the pathway rather than
      measuring it in these patients.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient 1 presented first during his infancy with episodes of irritability and lethargy associated with prolonged fasting that were responsive to feeding."
    explanation: >-
      A fasting-triggered, feeding-responsive symptom pattern is the clinical
      correlate of a failure to sustain the fasting state, though ketones were
      not measured during the episodes.
  downstream:
  - target: Fasting Intolerance
    causal_link_type: DIRECT
    description: >-
      Failure to sustain fasting metabolism presents clinically as intolerance
      of prolonged fasting, relieved by feeding.
  - target: Episodic Infantile Lethargy and Irritability
    causal_link_type: DIRECT
    description: >-
      The infantile episodes are the symptomatic expression of the fasting
      energy deficit, and remitted on feeding.
- name: Skeletal Muscle Energy Deficit
  biological_scale: TISSUE
  description: >-
    Muscle weakness, exercise intolerance and fatigability were present in all
    three reported patients and are the most consistent clinical feature of the
    disorder. In patient 1 the weakness was trunk- and proximal-predominant and
    accompanied by muscle wasting, ptosis and swallowing difficulty; muscle biopsy
    showed type 1 fibre predominance with normal mitochondrial morphology,
    respiratory chain enzyme activity and Gomori trichrome staining, so no
    structural myopathy or storage disease was demonstrated.
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he developed fine motor coordination delay, swallowing difficulty with frequent choking, bilateral ptosis, as well as exercise intolerance, intermittent muscle soreness, and generalized muscle weakness affecting mainly his trunk and proximal muscles"
    explanation: Documents the myopathic presentation in the index patient.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Myopathic, neurodevelopmental, and late-onset psychiatric manifestations are clinical hallmarks in our patients."
    explanation: Summarises the myopathic component as a defining feature across the cohort.
mechanistic_hypotheses:
- hypothesis_group_id: gamma_butyrobetaine_toxicity
  hypothesis_label: Gamma-butyrobetaine is independently toxic, not merely a marker
  status: EMERGING
  description: >-
    Under this model the accumulated substrate contributes to disease in its own
    right, in parallel with the carnitine deficit, plausibly by competing with
    carnitine for cellular uptake and so deepening the intracellular deficiency.
    The evidence is a C. elegans exposure experiment in which millimolar
    gamma-butyrobetaine killed gbh-1 null and functionally null embryos even on
    carnitine-producing bacteria, plus the clinical observation that
    gamma-butyrobetaine stays elevated on L-carnitine treatment. It is curated as
    EMERGING rather than canonical because the transporter-competition step is
    labelled presumed by the authors, the lethality data are invertebrate, and no
    human outcome has been shown to track gamma-butyrobetaine level. It matters
    therapeutically: if true, normalising carnitine alone would leave part of the
    disease untreated.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Translating results from the nematode model to human disease further allows the assumption that both L-carnitine deficiency and accumulation of γ-BB play an independent but synergistic role in the pathogenesis of human BBOX1 deficiency."
    explanation: States the two-arm hypothesis and, in the authors' own hedging, its status as an assumption carried over from the worm.
phenotypes:
- category: Cardiovascular
  name: Cardiomyopathy
  description: >-
    Mild cardiomyopathy in the index patient, which resolved by the age of 18
    years. Cardiomyopathy is the canonical organ manifestation of carnitine
    deficiency, so its presence here is expected even though only one of the
    three reported patients had it; the subtype was not characterised.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Mild, transient cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "He also developed a mild cardiomyopathy that resolved by the age of 18 years."
    explanation: >-
      Documents the cardiomyopathy and its resolution in the index patient, which
      is the whole basis for this phenotype.
  notes: >-
    Banded FREQUENT because one of three reported patients is 33%, inside the
    30-79% band, not the 5-29% OCCASIONAL band. See the entry-level notes on the
    frequency convention: every single-patient finding here is banded the same
    way. With a cohort of three the band carries almost no information; it is
    recorded for consistency rather than as an estimate.
- category: Metabolic
  name: Fasting Intolerance
  description: >-
    Intolerance of prolonged fasting in the index patient during infancy,
    presenting as symptomatic episodes that responded to feeding and remitted as
    he reached childhood. Not reported in the other two patients.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fasting intolerance
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient 1 presented first during his infancy with episodes of irritability and lethargy associated with prolonged fasting that were responsive to feeding."
    explanation: >-
      The prose sentence that makes the claim: symptoms tied to prolonged fasting
      and relieved by feeding, which is what fasting intolerance names. Table 1
      records the same finding as "Fasting intolerance+ (infancy)" for patient 1
      and absent in patients 2 and 3, but that cell is not quoted here - the
      table's columns are separated by em spaces and do not survive text
      extraction as a readable row.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: REFUTE
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hypoglycemia was not documented, and symptoms improved as he reached childhood."
    explanation: >-
      The prose denies documented hypoglycemia in the same patient whose Table 1
      column marks it present. Carried as a REFUTE item against the hypoglycemic
      reading of these episodes, so the report's internal disagreement is curated
      rather than silently resolved.
  notes: >-
    Left unbound deliberately. HPO has no term for fasting intolerance: a search
    of the HP label cache for "fasting" returns only HP:0003162 "Fasting
    hypoglycemia", and binding that would assert hypoglycemia, which is the one
    thing this report contradicts itself about. The prose states "Hypoglycemia
    was not documented" for this patient while Table 1 marks hypoglycemia "+" in
    his column. The prose side is carried as a REFUTE evidence item above; the
    Table 1 side is recorded here rather than as a snippet, because that table's
    columns are separated by em spaces and a single cell is not a quotable
    propositional sentence. Either way the disagreement stays visible instead of
    being settled by the choice of ontology term.
- category: Neurologic
  name: Episodic Infantile Lethargy and Irritability
  description: >-
    Episodes of irritability and lethargy in infancy, triggered by prolonged
    fasting and responsive to feeding, in the index patient. The episodes
    improved as he reached childhood. Distinct from the narcolepsy-like attacks
    recorded in the same patient from age 6.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Fasting-triggered episodes of lethargy and irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient 1 presented first during his infancy with episodes of irritability and lethargy associated with prolonged fasting that were responsive to feeding."
    explanation: >-
      Documents the episodes, their fasting trigger, and their response to
      feeding, which is what ties them to the hepatic ketogenesis arm.
  notes: >-
    Bound to HP:0000737 Irritability, which captures only half of the episode.
    HP:0011973 "Paroxysmal lethargy" would capture the other half and drop the
    irritability; neither term covers the compound episode, and the slot takes
    one term. The preferred_term carries the full description.
- category: Musculoskeletal
  name: Muscle Weakness
  description: >-
    Generalised muscle weakness, trunk- and proximal-predominant in the index
    patient, reported in all three patients.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At 4 years of age, she started having muscle weakness, exercise intolerance, and impaired gait."
    explanation: Documents muscle weakness in the second affected sibling.
- category: Musculoskeletal
  name: Exercise Intolerance
  description: Reduced tolerance of physical exertion, reported in all three patients.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was a history of fatigability and intolerance to physical exercise."
    explanation: Documents exercise intolerance in the family 2 proband.
- category: Constitutional
  name: Fatigability
  description: >-
    Abnormal fatigability, improved by L-carnitine supplementation in the one
    patient in whom the response was recorded.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There was a history of fatigability and intolerance to physical exercise."
    explanation: Documents fatigability as a presenting complaint.
- category: Musculoskeletal
  name: Muscle Soreness
  description: Intermittent muscle soreness, reported in the index patient.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "as well as exercise intolerance, intermittent muscle soreness, and generalized muscle weakness affecting mainly his trunk and proximal muscles"
    explanation: Documents intermittent muscle soreness alongside the other myopathic features in the index patient.
- category: Ophthalmologic
  name: Bilateral Ptosis
  description: Bilateral ptosis, developing at age 6 years in the index patient.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "he developed fine motor coordination delay, swallowing difficulty with frequent choking, bilateral ptosis"
    explanation: Documents ptosis in the index patient.
- category: Gastrointestinal
  name: Swallowing Difficulty
  description: Swallowing difficulty with frequent choking, reported in the two affected siblings.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "swallowing difficulty with frequent choking"
    explanation: Documents dysphagia in the index patient.
- category: Neurodevelopmental
  name: Motor Delay
  description: Fine motor coordination delay, reported in all three patients.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At 6 years, he developed fine motor coordination delay"
    explanation: Documents fine motor delay in the index patient.
- category: Neurodevelopmental
  name: Speech and Language Delay
  description: Language delay with learning difficulties, reported in the family 2 proband.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient presented at age 4 years with language delay, learning difficulties and was later diagnosed with autism spectrum disorder."
    explanation: Documents speech delay and learning difficulty in the family 2 proband.
- category: Neurodevelopmental
  name: Autism Spectrum Disorder
  description: >-
    Autism spectrum disorder in the family 2 proband. Note that autism is also the
    phenotype associated with TMLHE deficiency at the opposite end of the same
    biosynthetic pathway, so the association is of interest but rests here on a
    single patient.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was later diagnosed with autism spectrum disorder"
    explanation: Documents the autism diagnosis in the family 2 proband.
- category: Psychiatric
  name: Psychosis
  description: >-
    Episodes of psychosis from age 23 years in the index patient - the late-onset
    psychiatric manifestation the authors highlight.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Since the age of 23 years, he has been seen for episodes of psychosis and one episode of ketamine-induced seizures."
    explanation: Documents adult-onset psychosis in the index patient.
- category: Psychiatric
  name: Anxiety
  description: >-
    Severe anxiety in young adulthood, reported in the second sibling and in the
    family 2 proband.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "As a young adult, she developed severe anxiety."
    explanation: Documents severe anxiety in the second affected sibling.
- category: Neurologic
  name: Migraine
  description: Migraine headaches in childhood, reported in the second affected sibling.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Migraine
    term:
      id: HP:0002076
      label: Migraine
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patient 2 was seen during her childhood for migraine headaches, coordination difficulty, and dyslexia, requiring assistance at school."
    explanation: Documents migraine in the second affected sibling.
biochemical:
- name: Plasma free and total L-carnitine
  presence: DECREASED
  context: >-
    Persistently low free and total L-carnitine in serum and dried blood spots is
    the finding that brings these patients to metabolic attention. On its own it is
    not discriminating - it is shared with SLC22A5 transporter deficiency and with
    secondary carnitine depletion - so it must be paired with a normal renal
    fractional excretion and an elevated gamma-butyrobetaine to point at BBOX1.
  biomarker_term:
    preferred_term: carnitine
    term:
      id: CHEBI:17126
      label: carnitine
  readouts:
  - target: Systemic L-Carnitine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Low circulating free carnitine is the direct circulating readout of the
      systemic carnitine deficit.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biochemical genetic workup revealed persistently low levels of serum free carnitine."
    explanation: Documents the low circulating carnitine that defines the biochemical phenotype.
- name: Plasma and urinary gamma-butyrobetaine
  presence: INCREASED
  context: >-
    Elevated gamma-butyrobetaine, the substrate of the blocked reaction, is the
    disorder-specific marker. Reported plasma values in the two patients measured
    before supplementation were 5.50 and 13.20 umol/L against a 0.3-1.4 umol/L
    reference interval, and the elevation persisted during L-carnitine treatment.
    It is measured in specialised laboratories rather than on a routine
    acylcarnitine panel, which is why the diagnosis is easy to miss.
  biomarker_term:
    preferred_term: gamma-butyrobetaine
    term:
      id: CHEBI:16244
      label: 4-(trimethylammonio)butanoate
  readouts:
  - target: Gamma-Butyrobetaine Accumulation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      Plasma and urinary gamma-butyrobetaine directly report accumulation of the
      unconverted substrate upstream of the enzymatic block.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showing elevation of γ-BB in plasma (Table 1) and urine (data not shown) while plasma L-carnitine levels were within the normal range"
    explanation: Shows that gamma-butyrobetaine stays elevated even when supplementation has normalised carnitine, making it the more robust marker.
- name: Renal fractional excretion of carnitine
  presence: NORMAL
  context: >-
    A normal fractional excretion of carnitine (below 5%) is the discriminating
    negative finding. It excludes SLC22A5/OCTN2 transporter deficiency, in which
    carnitine is wasted in the urine, and so redirects the workup from transport to
    biosynthesis. All three reported patients had values between 0.7 and 2.9%.
  biomarker_term:
    preferred_term: carnitine
    term:
      id: CHEBI:17126
      label: carnitine
  readouts:
  - target: Systemic L-Carnitine Deficiency
    relationship: READOUT_OF
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: >-
      A normal value establishes that the carnitine deficit is not caused by renal
      wasting, which is what makes a biosynthetic defect the remaining explanation.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had low serum L-carnitine levels in the presence of a normal renal extraction fraction of carnitine"
    explanation: Documents the normal fractional excretion alongside low carnitine in the second sibling.
genetic:
- name: BBOX1
  gene_term:
    preferred_term: BBOX1
    term:
      id: hgnc:964
      label: BBOX1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  frequency: All three reported patients
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  notes: >-
    BBOX1 maps to 11p14.2 and encodes a 387-amino-acid cytosolic dioxygenase.
    Note that the 2025 report states the gene is on the short arm of chromosome 14;
    that is an error in the paper, and both HGNC and the earlier deletion case
    place BBOX1 at 11p14.2. The p.Gly263Arg allele reaches about 1% frequency in
    the Indigenous Background Variant Library and may be a founder variant, so its
    interpretation in First Nations patients requires population-matched frequency
    data rather than gnomAD alone.
  variants:
  - name: NM_003986.3:c.176A>G (p.Asp59Gly)
    description: >-
      Paternally inherited missense allele in family 1, predicted damaging by SIFT,
      PolyPhen-2 and CADD. The equivalent C. elegans allele retained normal
      function, so this allele is best regarded as hypomorphic.
  - name: NM_003986.3:c.675delA (p.Gly227Valfs*6)
    description: >-
      Maternally inherited frameshift allele in family 1, predicted to truncate the
      protein at 231 residues.
  - name: NM_003986.3:c.787G>A (p.Gly263Arg)
    description: >-
      Homozygous missense allele in the family 2 proband; present at about 1% in the
      Indigenous Background Variant Library and possibly a founder variant.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "revealed a homozygous variant of uncertain significance in BBOX1 NM_003986.3:c.787G>A (p.Gly263Arg)"
    explanation: Documents the third disease allele, homozygous in the family 2 proband.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "suggesting that it may be a founder variant of community significance"
    explanation: Records the population-frequency caveat attached to the p.Gly263Arg allele.
treatments:
- name: Oral L-carnitine supplementation
  description: >-
    Oral L-carnitine at 50-100 mg/kg/day normalised serum free carnitine in the
    family 2 proband and was accompanied by improvement in muscle weakness and
    fatigability. It does not lower gamma-butyrobetaine, so it addresses only one
    of the two proposed pathogenic arms. Evidence is a single documented clinical
    response, and that patient was subsequently lost to follow-up, so durability is
    unknown.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: L-carnitine supplementation
    term:
      id: NCIT:C15433
      label: Nutritional Support
    therapeutic_agent:
    - preferred_term: levocarnitine
      term:
        id: CHEBI:16347
        label: (R)-carnitine
  target_mechanisms:
  - target: Systemic L-Carnitine Deficiency
    treatment_effect: RESTORES
    description: >-
      Exogenous L-carnitine bypasses the blocked biosynthetic step and restores
      circulating carnitine, which is the arm of the mechanism it can reach.
    evidence:
    - reference: PMID:41022783
      reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "normalized serum free L-carnitine levels and improved fatigability and muscle weakness"
      explanation: Documents biochemical correction and symptomatic improvement on supplementation.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with L-carnitine resulted in the correction of L-carnitine deficiency in all our patients."
    explanation: Establishes that supplementation corrects the carnitine deficit across the cohort.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "while the degree of γ-BB accumulation in the plasma remained unchanged upon L-carnitine supplementation"
    explanation: Shows the treatment leaves gamma-butyrobetaine accumulation untouched, so it is not a complete correction of the biochemical phenotype.
animal_models:
- name: gbh-1 null C. elegans
  species: Caenorhabditis elegans
  genotype: gbh-1(ko), full deletion of the BBOX1-orthologue coding sequence
  genes:
  - preferred_term: BBOX1
    term:
      id: hgnc:964
      label: BBOX1
  description: >-
    CRISPR/Cas9 knockout of gbh-1, the C. elegans orthologue of BBOX1 (33%
    sequence identity, with the residues altered in the patients invariant across
    species). The strain has no L-carnitine, more than 50-fold elevated
    gamma-butyrobetaine and an absent acylcarnitine spectrum, and shows
    nutrition-dependent embryonic lethality that is fully rescued by exogenous
    L-carnitine. Its value is that the worm's exogenous carnitine supply can be
    controlled - an E. coli caiA mutant that cannot make carnitine was used to
    remove it - which is the manipulation that separates the biosynthetic defect
    from dietary compensation. Its limits are the obvious ones: an invertebrate,
    a null rather than a patient allele, and an embryonic-lethality readout that
    has no counterpart in the human phenotype.
  publication: PMID:41022783
  modeled_mechanisms:
  - target: Blocked Final Step of Endogenous L-Carnitine Biosynthesis
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Complete loss of the orthologous enzyme reproduces the selective terminal
      block: no L-carnitine, accumulated gamma-butyrobetaine, unchanged upstream
      precursors.
    limitations: >-
      Invertebrate system with a null allele; the corresponding human patients are
      hypomorphic compound heterozygotes or homozygotes for a missense allele, and
      no human tissue measurement of the biosynthetic block exists.
    readouts:
    - name: L-carnitine level by HPLC-MS
      target: Blocked Final Step of Endogenous L-Carnitine Biosynthesis
      direction: ABOLISHED
      interpretation: >-
        Undetectable L-carnitine is the direct product-side readout of the terminal
        block.
      evidence:
      - reference: PMID:41022783
        reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "L-carnitine is undetectable in gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) strains, indicating a disruption in its biosynthesis."
        explanation: Reports the measured loss of product in the null and functionally null strains.
    - name: Gamma-butyrobetaine level by HPLC-MS
      target: Blocked Final Step of Endogenous L-Carnitine Biosynthesis
      direction: INCREASED
      interpretation: >-
        Substrate accumulation above 50-fold is the substrate-side readout of the
        same block.
      evidence:
      - reference: PMID:41022783
        reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The gbh-1(ko), gbh-1(G247Vfs*6), and gbh-1(G283R) strains exhibited profound accumulation of γ-BB, with levels more than 50-fold above those seen in wild-type N2 nematodes"
        explanation: Quantifies substrate accumulation in the model.
    evidence:
    - reference: PMID:41022783
      reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "we observed a lethal embryonic phenotype for the gbh-1 loss-of-function strains, which was rescued upon L-carnitine supplementation"
      explanation: The carnitine rescue is what makes the model informative for the biosynthetic block rather than for gene loss in general.
  - target: Carnitine Transport Inhibition by Gamma-Butyrobetaine
    relationship: PERTURBS
    fidelity: LOW
    description: >-
      Exogenous gamma-butyrobetaine exposure is used as a direct perturbation to
      ask whether the accumulated substrate is harmful independently of the
      carnitine deficit; millimolar exposure was lethal to the null and
      functionally null strains on carnitine-replete bacteria.
    limitations: >-
      A millimolar external exposure is far above the low-micromolar plasma
      elevations seen in patients, the readout is embryonic viability rather than
      carnitine uptake, and the proposed transporter-competition step was not
      measured.
    readouts:
    - name: Embryonic hatch rate under gamma-butyrobetaine exposure
      target: Carnitine Transport Inhibition by Gamma-Butyrobetaine
      direction: DECREASED
      interpretation: >-
        Loss of viability on carnitine-replete food is the observation that
        motivates an independent toxicity arm.
      evidence:
      - reference: PMID:41022783
        reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "A complete F1 embryonic lethality for gbh-1(ko), gbh-1(G247Vfs6), and gbh-1(G283R) worms at a 1 mM concentration of γ-butyrobetaine"
        explanation: Reports the exposure result underlying the toxicity hypothesis.
    evidence:
    - reference: PMID:41022783
      reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: MODEL_ORGANISM
      snippet: "This pronounced vulnerability, even in the presence of the carnitine-producing E coli strain that served as a nutritional source, points to primary γ-BB toxicity."
      explanation: The authors' own interpretation of the perturbation as evidence for primary substrate toxicity.
- name: gbh-1 patient-allele knock-in C. elegans
  species: Caenorhabditis elegans
  genotype: gbh-1(D72G), gbh-1(G283R) and gbh-1(G247Vfs*6) knock-in strains modelling p.Asp59Gly, p.Gly263Arg and p.Gly227Valfs*6
  genes:
  - preferred_term: BBOX1
    term:
      id: hgnc:964
      label: BBOX1
  description: >-
    CRISPR/Cas9 knock-in strains carrying worm equivalents of the three patient
    alleles. G283R and G247Vfs*6 genocopy the null. D72G, the equivalent of the
    p.Asp59Gly allele that both family 1 siblings carry, has normal embryonic
    viability, normal L-carnitine and only a roughly 2-fold gamma-butyrobetaine
    rise, and worms carrying D72G in trans with the frameshift allele - the actual
    patient genotype - showed no lethality at all.
  publication: PMID:41022783
  modeled_mechanisms:
  - target: BBOX1 Loss of Function
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Two of the three patient alleles behave as functional nulls in the worm,
      which is the functional evidence supporting their pathogenicity; the third
      does not.
    limitations: >-
      Allele-level fidelity is uneven, and the compound-heterozygous genotype of
      the two family 1 patients produces no phenotype in this system.
    readouts:
    - name: Embryonic hatch rate of patient-allele strains
      target: BBOX1 Loss of Function
      direction: DECREASED
      interpretation: >-
        Genocopying the knockout is the functional criterion used to call G283R and
        G247Vfs*6 pathogenic.
      evidence:
      - reference: PMID:41022783
        reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "gbh-1(G283R) and gbh-1(G247Vfs*6) genocopied the knockout, exhibiting nutrition-dependent embryonic lethality"
        explanation: Establishes the functional-null behaviour of two patient alleles.
    evidence:
    - reference: PMID:41022783
      reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These results strongly suggest that gbh-1(G283R) and gbh-1(G247Vfs*6) are functional alleles."
      explanation: The authors' functional conclusion for the two alleles that behave as nulls.
  - target: Skeletal Muscle Energy Deficit
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      The worm strains carrying the family 1 compound-heterozygous genotype are
      phenotypically normal, and no strain reproduces the myopathic phenotype that
      defines the human disease; the readout available in this system is embryonic
      viability.
    limitations: >-
      C. elegans body-wall muscle is not a model of human skeletal muscle
      physiology, no muscle-specific measurement was made, and the D72G/G247Vfs*6
      trans-heterozygote - the genotype of the two most fully characterised
      patients - had no phenotype even under starvation. The model therefore
      supports the biochemical lesion but does not connect it to the clinical
      phenotype.
    evidence:
    - reference: PMID:41022783
      reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "double-heterozygous-mutant worms carrying both the D72G and G247Vfs*6 alleles (modeling the two patients carrying the compound heterozygous variants) showed no embryonic lethality, even under prior starvation"
      explanation: The patient genotype produces no phenotype in the model, which is the failure being recorded.
    - reference: PMID:41022783
      reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "direct translation of this data to human conditions warrants caution"
      explanation: The authors' own statement of the model's translational limits.
discussions:
- discussion_id: bbox1_genotype_phenotype_penetrance
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does biallelic loss of BBOX1 reliably cause clinical disease, or is the
    myopathic and neuropsychiatric phenotype dependent on modifiers, dietary
    carnitine intake, or ascertainment?
  attaches_to:
  - pathophysiology#BBOX1 Loss of Function
  - pathophysiology#Systemic L-Carnitine Deficiency
  rationale: >-
    Three lines of evidence pull against a simple fully-penetrant model. An
    individual homozygous for a 221 kb 11p14.2 deletion removing BBOX1 outright had
    only a borderline-low free carnitine, a normal acylcarnitine-to-free-carnitine
    ratio and none of the classic carnitine-deficiency manifestations, and the
    authors of that report concluded that dietary intake and renal reabsorption
    suffice for carnitine homeostasis. Homozygous predicted-truncating BBOX1
    alleles are present in gnomAD. And the family 1 patients are compound
    heterozygous for an allele that retains function in the orthologous worm assay.
    Since the biosynthetic arm is only one of three inputs to carnitine
    homeostasis, dietary carnitine intake is a plausible modifier that no reported
    case controls for. Resolving this matters for whether BBOX1 should be added to
    metabolic gene panels and for how a homozygous truncating variant found
    incidentally should be reported.

    A fourth line, and the one most specific to this cohort: two of the three
    patients carry additional variants in fatty-acid-oxidation genes, and the
    causal chain proposed here runs through carnitine-dependent fatty acid
    oxidation, so those variants are candidate confounders rather than incidental
    findings. Patient 3 is homozygous for CPT1A NM_001876.4:c.1436C>T
    (p.Pro479Leu), which the authors state is associated with a mild form of
    carnitine palmitoyl transferase I deficiency and puts homozygotes at risk of
    fasting hypoglycemia; the same authors note that patient 3's symptoms have not
    been associated with that variant, so this is a confound they considered and
    argued against rather than one they overlooked. The variant is common in the
    Indigenous Background Variant Library at roughly 11% allele frequency, which
    matters for how much weight a rarity-based pathogenicity argument can carry in
    this population. Patient 1 additionally carries a heterozygous ACADL
    frameshift (NM_001608.4:c.1018_1019del, p.His340Tyrfs*16) and an RYR1 variant
    of uncertain significance (NM_000540.3:c.10171G>A, p.Glu3391Lys) - the first in
    long-chain acyl-CoA dehydrogenase, immediately downstream of the carnitine
    shuttle, and the second in a gene whose phenotypes include exercise
    intolerance and myopathy, which are this entry's most consistent features.
    Neither is called causal by the authors, and a single heterozygous ACADL
    allele is not expected to be, but in a three-patient cohort they bound how
    confidently any individual feature can be attributed to BBOX1 alone.
  evidence:
  - reference: PMID:24986124
    reference_title: "The effect of homozygous deletion of the BBOX1 and Fibin genes on carnitine level and acyl carnitine profile."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "This condition results in mildly decreased free carnitine level, but not in clinical manifestations characteristic of carnitine deficiency disorders, suggesting that dietary carnitine intake and renal reabsorption are sufficient to carnitine homeostasis."
    explanation: A complete BBOX1 deletion produced no classic carnitine-deficiency phenotype, arguing against obligate clinical consequence.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "have been found in homozygous individuals in the population database gnomAD, posing the question of whether these individuals may have milder phenotypes, possibly due to modifier effects"
    explanation: The authors themselves raise unaffected or mildly affected homozygous truncating carriers as an open question.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is associated with a mild form of carnitine palmitoyl transferase I deficiency, putting homozygous individuals at risk for fasting hypoglycemia"
    explanation: >-
      Establishes that patient 3's homozygous CPT1A p.Pro479Leu genotype is
      itself a fatty-acid-oxidation disorder allele, which is why it is treated
      here as a candidate confounder of that patient's phenotype.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: REFUTE
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "The symptoms observed in patient 3 have not been associated with this variant."
    explanation: >-
      The authors' own argument against the CPT1A confound. Carried as REFUTE
      against the proposition that CPT1A explains patient 3's presentation, so
      both sides of the confounding question are recorded.
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional heterozygous variants included a variant of uncertain significance in RYR1"
    explanation: >-
      Documents the additional RYR1 and ACADL variants in patient 1, both in
      genes whose phenotypes overlap this entry's myopathic features.
- discussion_id: bbox1_neuropsychiatric_attribution
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Are the neurodevelopmental and psychiatric features mechanistically caused by
    BBOX1 deficiency, and if so through what route - brain carnitine depletion,
    gamma-butyrobetaine toxicity, or neither?
  attaches_to:
  - phenotypes#Autism Spectrum Disorder
  - phenotypes#Psychosis
  - pathophysiology#Gamma-Butyrobetaine Accumulation
  rationale: >-
    The report singles out neurodevelopmental and psychiatric manifestations as
    specific to BBOX1 deficiency, in contrast to the myopathic features it shares
    with SLC22A5 disease. But no mechanistic route is curated here because none has
    been demonstrated: the supporting arguments offered are an association of BBOX1
    polymorphisms with schizophrenia susceptibility and downregulation of BBOX1 in
    a mouse schizophrenia model, neither of which establishes that carnitine
    depletion or substrate accumulation in the brain produces these features. The
    cohort is three patients from two families with heterogeneous presentations -
    autism and learning difficulty in one, psychosis in another, anxiety in two -
    which is not enough to separate a causal effect from coincidence. TMLHE
    deficiency at the first step of the same pathway carries a comparable and
    similarly unresolved autism association, so this is a pathway-level question
    rather than a BBOX1-specific one.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "additional neurodevelopmental and psychiatric manifestations seem to be specifically related to BBOX1 deficiency"
    explanation: States the attribution claim in the hedged form that makes it a knowledge gap rather than a curated mechanism.
- discussion_id: bbox1_worm_model_translational_validity
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Can the C. elegans gbh-1 model support causal claims about human BBOX1
    disease when the worm equivalent of the patients' compound-heterozygous
    genotype is phenotypically normal?
  attaches_to:
  - animal_models#gbh-1 patient-allele knock-in C. elegans
  - pathophysiology#Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
  rationale: >-
    The worm model carries most of the causal weight in this first report: it is
    where the biosynthetic block, the substrate accumulation and the carnitine
    rescue are demonstrated. Yet the strain modelling p.Asp59Gly behaves as wild
    type on every assay, and the trans-heterozygote reproducing the family 1
    genotype shows no lethality even under starvation, so the model does not
    reproduce the disease state of the two most fully characterised patients. The
    human data are also partly discordant with a downstream fatty-acid-oxidation
    block: patient 1's palmitate-loaded fibroblasts had a normal acylcarnitine
    profile, whereas the worm strains lose the acylcarnitine pool entirely. This is
    a mismatch of translational validity rather than an absence of evidence - the
    experiments were done, and they do not line up - so it is curated as
    HUMAN_MODEL_MISMATCH. Resolving it needs a mammalian model or a human
    tissue-level measurement of carnitine-dependent fatty acid oxidation.
  proposed_experiments:
  - experiment_id: exp_bbox1_muscle_fao_flux
    name: Human muscle carnitine and fatty-acid-oxidation flux in a BBOX1 patient
    description: >-
      Measure muscle total and free carnitine plus long-chain fatty acid oxidation
      flux in a biopsy from a molecularly confirmed patient sampled before starting
      or after a supervised washout of L-carnitine, against matched controls. This
      is the measurement that would put the human arm of the shuttle step on direct
      evidence rather than on inference from carnitine's known role, and it would
      also address the discordance with the normal fibroblast acylcarnitine
      profile, since fibroblasts are not the tissue in which the phenotype
      manifests.
    would_support:
    - pathophysiology#Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
    supporting_outcome:
    - >-
      Reduced muscle carnitine content with reduced long-chain fatty acid oxidation
      flux relative to controls, correcting on resupplementation, would establish
      the shuttle step in human tissue.
    would_refute:
    - pathophysiology#Reduced Carnitine Shuttle Flux and Impaired Fatty Acid Beta-Oxidation
    refuting_outcome:
    - >-
      Normal muscle carnitine content and normal oxidation flux despite low plasma
      carnitine would locate the myopathy outside the carnitine shuttle and force a
      different account of the muscle phenotype.
  evidence:
  - reference: PMID:41022783
    reference_title: "Biallelic variants in BBOX1 cause L-Carnitine deficiency and elevated γ-butyrobetaine."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "By contrast, gbh-1(D72G) mutants displayed wild-type embryonic viability under all conditions tested"
    explanation: The patient-derived allele carried by both family 1 siblings is functionally silent in the model, which is the mismatch.
notes: >-
  MONDO anchor: none. As of the 2025 first report there is no MONDO class and no
  OMIM phenotype entry for BBOX1-related carnitine biosynthesis deficiency - OMIM
  603312 is the BBOX1 gene record (a star entry), not a phenotype. The entry is
  therefore left without a top-level disease_term rather than being anchored to a
  neighbouring class that would misstate it: MONDO:0017716 "disorder of carnitine
  cycle and carnitine transport" is a sibling concept, not a parent, because this
  is a biosynthetic defect rather than a cycle or transport defect, and
  MONDO:0008919 "systemic primary carnitine deficiency disease" is the SLC22A5
  transporter disorder this entry is explicitly distinguished from. A MONDO new
  term request has been drafted on issue #5565 for a curator to forward upstream;
  this entry should be repointed once a class exists. See the decision-rule
  discussion on issue #3881 and the anchor backlog in issue #3691.

  Nosology: this is the second curated defect of endogenous carnitine
  biosynthesis, alongside TMLHE deficiency at the first step of the same four-step
  pathway. The two are biochemically complementary - TMLHE deficiency reduces the
  HTML/TML ratio, BBOX1 deficiency raises gamma-butyrobetaine - and neither is
  detected by a routine acylcarnitine panel. It is kept separate from
  Primary_Carnitine_Deficiency (SLC22A5) because the lesion, the biochemical
  signature and the discriminating test (renal fractional carnitine excretion) all
  differ, even though both present with low circulating carnitine and myopathy.

  Curated from IEMbase metabolic work package WP-010, row 4.1.06.01. A previous
  audit of that package deferred this row pending confirmation that a citable
  human clinical case exists; PMID:41022783 is that confirmation.

  Frequency bands: the whole cohort is three patients, so every band here is one
  of 1/3 (33%), 2/3 (67%) or 3/3 (100%). The first two both fall inside
  FrequencyEnum's FREQUENT band (30-79%), which is why no phenotype in this
  entry is banded OCCASIONAL (5-29%) - a single-patient finding in a
  three-patient cohort is 33%, not 5-29%. Six single-patient findings were
  initially banded OCCASIONAL and corrected. Read every band here as a
  denominator artifact rather than as a population estimate; they will need
  redoing against the first real cohort.

  No deep-research artifact. `research/` carries no BBOX1 report, and none was
  run for this entry. The literature is one 2025 clinical report of three
  patients (PMID:41022783), one 2014 deletion case (PMID:24986124) and one 2002
  pathway review (PMID:11802770), all three cached and cited here; the disease
  had no published clinical description at all before 2025, so a deep-research
  sweep has almost nothing to retrieve beyond what this entry already consumes.
  The completeness gaps found in review were misses from inside the cited paper
  rather than missing literature, which a DR run would not have caught. Recorded
  here so the absence reads as a scoped decision rather than a skipped step; a
  DR run becomes worthwhile once a second independent cohort is published.